A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS) - ENFORCE

CHIP - Rigshospitalet - University of Copenhagen0 个研究点目标入组 1,000 人开始时间: 2021年6月11日最近更新: 2024年3月12日

试验速览

暂无简介。

•1.Written informed consent obtained before any trial related procedures are performed
•2.Male or female eligible for SARS-CoV-2 immunization (as defined by SST in the national vaccination plan/Tilvalgsordningen)
•3.The subject must be willing and able to comply with trial protocol (re-visits and biological samples)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1000
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Male and female under the age of 18
•2.Any subgroup of individuals for which the vaccines are contra-indicated
•3.Previous SARS-CoV-2 vaccination
•Specific for the Johnson & Johnson vaccine:
•4.Experience of a serious allergic reaction after injection of any other vaccine
•5.Serious infection with high fever (> 38 0C)
•A temporary postponement of the vaccination is allowed, when participant has been well for at least 48 hours. Mild fever or upper airway infection like a cold is not a problem
•6.Problems with bleeding or bruising, or use of anticoagulant medicine (to prevent blood clots)
•7.Immunodeficiency or use of medicines that weaken the immune system (such as high-dose corticosteroids, immunosuppressants or cancer medicines)

发起方

CHIP - Rigshospitalet - University of Copenhagen